Literature DB >> 10652600

Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs.

S Orlowski1, M Garrigos.   

Abstract

P-glycoprotein (P-gp) is an active, ATP-dependent plasma membrane transporter which is responsible for the expulsion of various cytotoxic drugs with different chemical structures out of resistant (MDR) cells. It is also capable of transporting a number of other amphiphilic molecules, the so-called MDR-reversing agents, which belong to a very broad variety of chemical families. Moreover, P-gp can also play a role in steroid secretion and cellular detoxification by transporting various other substrates. In this review, we address the problem of the multiple recognition by P-gp of such a large number of amphiphilic molecules. This is both (i) from a basic viewpoint in order to discuss the underlying molecular mechanisms explaining how the general rule of substrate-enzyme specificity can be violated, and (ii) from a more applied pharmacological viewpoint to show in detail how the interaction of various drugs with P-gp leads to important consequences in terms of the relative effects of these drugs in the anticancer chemotherapy context, as well as for their pharmacokinetic distributions in the whole organism, rationalizing possible adverse drug reactions. In particular, we will present evidence that, independently of the technique used, the mutual interactions between P-gp transport substrates cannot always be reduced to simple competitive effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10652600

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux.

Authors:  José M Pérez-Victoria; Fernando Cortés-Selva; Adriana Parodi-Talice; Boris I Bavchvarov; F Javier Pérez-Victoria; Francisco Muñoz-Martínez; Mathias Maitrejean; M Paola Costi; Denis Barron; Attilio Di Pietro; Santiago Castanys; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Biomimetic Design of Protein Nanomaterials for Hydrophobic Molecular Transport.

Authors:  Dongmei Ren; Mercè Dalmau; Arlo Randall; Matthew M Shindel; Pierre Baldi; Szu-Wen Wang
Journal:  Adv Funct Mater       Date:  2012-04-23       Impact factor: 18.808

3.  Fexofenadine hydrochloride in the treatment of allergic disease: a review.

Authors:  David Axelrod; Leonard Bielory
Journal:  J Asthma Allergy       Date:  2008-09-19

4.  Expression of multidrug resistance proteins in invasive ductal carcinoma of the breast.

Authors:  Weiquan Li; Maomin Song
Journal:  Oncol Lett       Date:  2014-08-11       Impact factor: 2.967

Review 5.  High drug-loading nanomedicines: progress, current status, and prospects.

Authors:  Shihong Shen; Youshen Wu; Yongchun Liu; Daocheng Wu
Journal:  Int J Nanomedicine       Date:  2017-05-31

6.  Binding site of ABC transporter homology models confirmed by ABCB1 crystal structure.

Authors:  Aina W Ravna; Ingebrigt Sylte; Georg Sager
Journal:  Theor Biol Med Model       Date:  2009-09-04       Impact factor: 2.432

7.  Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5).

Authors:  Aina W Ravna; Ingebrigt Sylte; Georg Sager
Journal:  Theor Biol Med Model       Date:  2007-09-06       Impact factor: 2.432

8.  Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy.

Authors:  Alicia Ponte-Sucre
Journal:  Kinetoplastid Biol Dis       Date:  2003-10-28

9.  New Evidence for P-gp-Mediated Export of Amyloid-β PEPTIDES in Molecular, Blood-Brain Barrier and Neuronal Models.

Authors:  Amanda B Chai; Anika M S Hartz; Xuexin Gao; Alryel Yang; Richard Callaghan; Ingrid C Gelissen
Journal:  Int J Mol Sci       Date:  2020-12-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.